8 These authors contributed equally to this work. 
Acquired resistance to imatinib in patients with chronic myeloid leukaemia (CML) or Philadelphia-positive (Ph þ ) acute lymphoblastic leukaemia frequently arises due to point mutations of the BCR-ABL kinase domain (KD) 1,2 so that, as new inhibitors with differential activity against KD mutant BCR-ABL become available, early detection and precise quantification of key mutations are likely to make an increasingly important contribution to patient-specific treatment decisions. A number of approaches have been developed in recent years to detect these mutations based on the techniques of DNA sequencing, denaturing high-performance liquid chromatography (DHPLC), mutation-specific PCR and mass array genotyping. However, although some of these assays can detect mutants in wild-type allele frequencies as low as 0.1% and others are quantitative, the combination of sensitivity and quantification has remained elusive. Reliable quantification has been provided to date by pyrosequencing, which has a detection limit of around 10% mutants in wild-type allele, and by some PCR-based approaches. 3 The potential importance of the quantitative detection of low-level mutations has become clear from the use of PCR-based approaches using mutation-specific primers, which have identified low-level KD mutations in the majority of Ph þ acute lymphoblastic leukaemia patients before therapy and revealed that almost all of those harbouring a low-level T315I or p-loop mutation at diagnosis relapsed with the same mutation, even after achieving a molecular remission on imatinib and chemotherapy. 2 Similar techniques have identified low-level, pretherapeutic KD mutations in CML, although the relevance to resistance and progression remains unclear. 4 Accurate quantification of low-level mutations is therefore likely to make an important contribution to our understanding and monitoring of disease progression.
In an attempt to combine high sensitivity and reliable quantification, we have now adapted the principle of allelespecific PCR by adding a ligation step to increase the specificity of the assay for the detection of mutant versus wild-type BCR-ABL. This allows the subsequent amplification procedure to be optimized for sensitivity without affecting specificity. On the basis of this development, we report here a new, highly sensitive and quantitative technique to detect BCR-ABL KD mutations and apply the technique for the detection of the key mutations, T315I (codon change ACT to ATT) and E255K (codon change GAG to AGG).
The principle employed for quantifying point mutations in BCR-ABL is based on the MLPA technique described earlier. 5 The three-step procedure is illustrated in Figure 1 . First, BCR-ABL sequences are amplified in a standard PCR ('accumulation PCR') as used for the detection of BCR-ABL-positive cells from cDNA. The second step involves stringent (high temperature) hybridization to this PCR product of two probes, A1 and A2, which span the mutation region of interest. Each probe consists of an ABL-hybridizing sequence (shown in black in Figure 1 ) flanked by a PCR primer-binding site (shown in dark grey in Figure 1 ). One of these probes (A1) carries the point mutation at the 3 0 -end, whereas the 5 0 -end of the other (A2) corresponds to the neighbouring base. A high-temperature ligation reaction serves to join these two probes only when there is no mismatch at the mutation site. Finally, the yield of ligated probe is determined by real-time PCR using primers complementary to the primer-binding sites at the non-ligated ends of the two probes. The optional inclusion of a 1-10 bp spacer between the ABL-binding and primer-binding ends of one of the probes (in our case A1) enables the probe pair-specific generation of PCR products of different lengths and melting temperatures. This permits the multiplex, real-time PCR amplification and direct comparison of ligation products originating from the mutationspecific probes with distinguishable products originating from a pair of internal control probes complementary to a non-mutated region (see Table 1 for probe details). The C t values at threshold 0.200 (Applied Biosystems 7300 system software, Darmstadt, Germany) are then compared directly to determine the different RNA transcript levels of BCR-ABL total and BCR-ABL mutation . To ensure comparability between the BCR-ABL total and BCR-ABL mutation specific assays, we first determined the PCR efficiency of each individual assay by measuring serial dilutions of 100% mutated BCR-ABL PCR products in triplicate. Interassay variation was investigated in three independent runs performed on 3 consecutive days. Only C t values between 18 and 37 were used for the calculation of ligation PCR (L-PCR) efficiency from the given slope using SDS 1.6.3 software (Applied Biosystems) according to the equation: PCR efficiency ¼ (10 [À1/slope] À1) Â 100. All three L-PCR assays displayed an efficiency between 94 and 99%. The parallel L-PCR amplification of mutation-specific and total BCR-ABL sequences therefore enables normalization of the mutation-specific C t values to those of total BCR-ABL and expression of the level of mutated sequences as a percentage of total BCR-ABL sequences. We used the comparative C t method to calculate the relative percentage of mutated cells directly according to the equation: % mutant allele ¼ 2
To establish sensitivity and specificity, the assay was performed on serial four-fold dilutions of BaF3 cells expressing the T315I or E255K mutants of BCR-ABL in BaF3 cells expressing wild-type BCR-ABL. In this experiment, detection of the 0.1% BCR-ABL T315I dilution (at C t 29.52) using mutantspecific probes was clearly distinguishable from that of the BCR-ABL wt control (at C t 30.79), demonstrating reliable detection of a mutant clone down to 0.1%. Importantly, the cross-reactivity of the BCR-ABL mutant probe to wild-type target varied in the range 0.01-0.05% between runs, but never exceeded 0.05%. In our experience, if the C t of the BCR-ABL total amplification using the wild-type probes exceeds 25, there is insufficient target for the specific PCR, which should then be repeated with a lower (1:500) dilution of the original accumulation PCR product. The dynamic range of the L-PCR approach, which is particularly important for the successful monitoring of a mutant clone, typically covers from 100 to less than 0.1% mutant (3-3.5 log). The robustness of the PCR conditions contributes to a very BCR-ABL accumulation (1), hybridization followed by ligation (2) and quantification (3).
Step 1: BCR-ABL is amplified using BCR Primer BCR-F1 (exon 10) or BCR-F2 (exon 1) and ABL primer ABL-R1 (exon 6), resulting in a template of 1055 (BCR F2), 1418 or 1478 bp (both BCR F1) for the e1 (m-BCR) or e13, e14 (M-BCR) BCR exons, respectively.
Step 2: subsequently, the probes A1 and A2 hybridize within the complementary strands (black). The 3 0 -OH end of the A1 probe matches the mutation site, with the phosphorylated 5 0 -end of the A2 probe immediately adjoining (2a). The conjunction (ligation) of A1 and A2 is only successful with perfectly matched probe pairs (2b).
Step 3: non-hybridized nucleotides (grey) of the ligated A1 and A2 probes provide the template for the universal real-time PCR primer for the subsequent Sybr green quantification of BCR-ABL total and BCR-ABL mutant (3).
low interassay variation in the calculated frequency of mutants of around 20% (0.2 log) over the entire detection range. Results for the T315I and E255K mutants were essentially the same. We conclude that the assay is highly reliable and should be equally applicable to other single-base mutations.
We then tested the performance of the L-PCR procedure against two established non-mutation-specific screening detection methods that do not allow accurate quantification: direct sequencing, 6 which has a relatively low sensitivity, and DHPLC, which is among the most sensitive, with a reported detection limit of 1-5% 7 down to 0.01%. 3 Eleven samples from Ph þ CML patients shown earlier by direct sequencing to carry either T315I or E255K mutations were re-analysed by L-PCR. Each of these was indeed confirmed by L-PCR to harbour the respective mutation and to be wild type at the other site (Table 2) . A median of 69.74% (range 20.00-95.17%) BCR-ABL T315I and 38.07% (range 25.35-38.33%) BCR-ABL E255K in total BCR-ABL was detected from these samples. In addition, one of four samples that had previously been identified as wild type by direct sequencing showed 0.39% BCR-ABL E255K by L-PCR. A repeat L-PCR analysis using newly synthesized cDNA from this sample showed comparable results of 0.32% BCR-ABL E255K , indicating reliable identification of a low-level mutation missed by direct sequencing.
A total of 20 blinded samples from Ph þ acute lymphoblastic leukaemia patients at or soon after diagnosis were then analysed independently by both L-PCR and DHPLC. Four samples (20%) were found by L-PCR to be positive for the T315I mutation, with a median of 22.67 (range 0.84-42.93%) mutants in wild type, whereas 8 samples (40%) were positive for the E255K mutation, with a median of 18.82 (range 0.12-74.74%) mutants in wild type. The remaining 8 samples (40%) were negative for both mutations (Table 2) . DHPLC results were found to be entirely concordant with all L-PCR results even in the three samples harbouring less than 1% mutated clone (Table 1) . This shows the sensitivity of L-PCR to be comparable with that of an independently performed DHPLC assay, with both approaches identifying mutations present at levels below 1%. We conclude that the L-PCR procedure offers a novel technique combining both sensitive and quantitative detection of specific point mutations in the BCR-ABL kinase domain.
The key feature of the L-PCR approach reported here is the amplification of a mutant-specific ligation product, which effectively focuses the requirement for specificity on a single 'all or nothing' ligation reaction rather than on repeated subsequent rounds of primer annealing and PCR. The most important limitations of the L-PCR technique are the need for specific ligation probes for each mutation of interest and the period of around 24 h required to complete the analysis. For these reasons, it is not a suitable technique for primary screening for the presence of unknown mutations throughout a large region. However, the L-PCR method is likely to prove particularly useful for the detection and monitoring of the relatively few mutations of specific relevance in the treatment response to a given tyrosine kinase inhibitor, and therefore to treatment decisions. With this aim, we are currently extending the panel of target mutations to include those such as Y252H/F Table 1 Ligation probes for mutation-specific and total BCR-ABL hybridization or F317L, which are associated with different sensitivity to both nilotinib and dasatinib. 8 Finally, the ability to detect low levels of BCR-ABL mutant clones in CML has recently led to the recognition that potentially relevant mutations such as T315I may be present at a low level without necessarily leading to drug resistance. This suggests the existence of subclones of Ph þ cells that make no long-term contribution to disease progression, raising questions concerning the functional heterogeneity of CML populations, the kinetics of clonal and subclonal evolution and the conditions under which the presence of a potentially relevant mutation may be expected to impact evolution of the disease. In each of these contexts, the quantitative monitoring of low levels of mutation over long periods using the L-PCR technique should be particularly informative.
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